Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03189836 · ClinicalTrials.gov registry record · Phase 1
Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
A Phase 1 study, sponsored by Cogent Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03189836 is a Phase 1 study that was terminated before completion, run by Cogent Biosciences. The registered enrollment target is 26 participants.
The verdict
NCT03189836, a Phase 1 study, was terminated before completion, sponsored by Cogent Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.
Interventions
- BIOLOGICAL rituximab
- BIOLOGICAL ACTR707
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2017-10-04 |
| Est. Completion | 2020-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03189836
The ClinicalTrials.gov registry entry for NCT03189836 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cogent Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rituximab is the first listed.
NCT03189836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03189836 about?
NCT03189836 is a clinical study titled "Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma". This is a phase 1, multi-center, single-arm, open-label study evaluating the safety and anti-lymphoma activity of an autologous T cell product (ACTR707) in combination with rituximab in subjects with refractory or relapsed CD20+ B cell lymphoma.
What is the current status of trial NCT03189836?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2017-10-04. Estimated completion is 2020-09-21.
What interventions are being tested in trial NCT03189836?
The interventions under investigation include: rituximab (BIOLOGICAL), ACTR707 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03189836?
This trial is sponsored by Cogent Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.